Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes.
Serruys PW, Onuma Y, Ormiston JA, de Bruyne B, Regar E, Dudek D, Thuesen L, Smits PC, Chevalier B, McClean D, Koolen J, Windecker S, Whitbourn R, Meredith I, Dorange C, Veldhof S, Miquel-Hebert K, Rapoza R, García-García HM. Serruys PW, et al. Circulation. 2010 Nov 30;122(22):2301-12. doi: 10.1161/CIRCULATIONAHA.110.970772. Epub 2010 Nov 15. Circulation. 2010. PMID: 21098436
Two-year clinical, angiographic, and intravascular ultrasound follow-up of the XIENCE V everolimus-eluting stent in the treatment of patients with de novo native coronary artery lesions: the SPIRIT II trial.
Claessen BE, Beijk MA, Legrand V, Ruzyllo W, Manari A, Varenne O, Suttorp MJ, Tijssen JG, Miquel-Hebert K, Veldhof S, Henriques JP, Serruys PW, Piek JJ. Claessen BE, et al. Circ Cardiovasc Interv. 2009 Aug;2(4):339-47. doi: 10.1161/CIRCINTERVENTIONS.108.831800.108.831800. Epub 2009 Jul 22. Circ Cardiovasc Interv. 2009. PMID: 20031737 Free article. Clinical Trial.
3-year clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT II trial (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions).
Garg S, Serruys P, Onuma Y, Dorange C, Veldhof S, Miquel-Hébert K, Sudhir K, Boland J, Huber K, Garcia E, te Riele JA; SPIRIT II Investigators. Garg S, et al. JACC Cardiovasc Interv. 2009 Dec;2(12):1190-8. doi: 10.1016/j.jcin.2009.10.002. JACC Cardiovasc Interv. 2009. PMID: 20129545 Free article. Clinical Trial.
Monitoring in vivo absorption of a drug-eluting bioabsorbable stent with intravascular ultrasound-derived parameters a feasibility study.
Bruining N, de Winter S, Roelandt JR, Regar E, Heller I, van Domburg RT, Hamers R, Onuma Y, Dudek D, Webster MW, Thuesen L, Ormiston JA, Cheong WF, Miquel-Hebert K, Veldhof S, Serruys PW. Bruining N, et al. JACC Cardiovasc Interv. 2010 Apr;3(4):449-56. doi: 10.1016/j.jcin.2010.02.004. JACC Cardiovasc Interv. 2010. PMID: 20398874 Free article. Clinical Trial.
Efficacy of everolimus eluting stent implantation in patients with calcified coronary culprit lesions: two-year angiographic and three-year clinical results from the SPIRIT II study.
Onuma Y, Tanimoto S, Ruygrok P, Neuzner J, Piek JJ, Seth A, Schofer JJ, Richardt G, Wiemer M, Carrié D, Thuesen L, Dorange C, Miquel-Hebert K, Veldhof S, Serruys PW. Onuma Y, et al. Catheter Cardiovasc Interv. 2010 Nov 1;76(5):634-42. doi: 10.1002/ccd.22541. Catheter Cardiovasc Interv. 2010. PMID: 20690152 Clinical Trial.
Temporal changes of coronary artery plaque located behind the struts of the everolimus eluting bioresorbable vascular scaffold.
Brugaletta S, Garcia-Garcia HM, Garg S, Gomez-Lara J, Diletti R, Onuma Y, van Geuns RJ, McClean D, Dudek D, Thuesen L, Chevalier B, Windecker S, Whitbourn R, Dorange C, Miquel-Hebert K, Sudhir K, Ormiston JA, Serruys PW. Brugaletta S, et al. Int J Cardiovasc Imaging. 2011 Jul;27(6):859-66. doi: 10.1007/s10554-010-9724-y. Epub 2010 Oct 13. Int J Cardiovasc Imaging. 2011. PMID: 20941544 Free article. Clinical Trial.
Serial in vivo intravascular ultrasound-based echogenicity changes of everolimus-eluting bioresorbable vascular scaffold during the first 12 months after implantation insights from the ABSORB B trial.
Brugaletta S, Gomez-Lara J, Serruys PW, Farooq V, van Geuns RJ, Thuesen L, Dudek D, Koolen J, Chevalier B, McClean D, Windecker S, Smits PC, de Bruyne B, Whitbourn R, Meredith I, van Domburg RT, Sihan K, de Winter S, Veldhof S, Miquel-Hebert K, Rapoza R, Garcia-Garcia HM, Ormiston JA, Bruining N. Brugaletta S, et al. Among authors: miquel hebert k. JACC Cardiovasc Interv. 2011 Dec;4(12):1281-9. doi: 10.1016/j.jcin.2011.08.014. JACC Cardiovasc Interv. 2011. PMID: 22192369 Free article. Clinical Trial.
Circumferential evaluation of the neointima by optical coherence tomography after ABSORB bioresorbable vascular scaffold implantation: can the scaffold cap the plaque?
Brugaletta S, Radu MD, Garcia-Garcia HM, Heo JH, Farooq V, Girasis C, van Geuns RJ, Thuesen L, McClean D, Chevalier B, Windecker S, Koolen J, Rapoza R, Miquel-Hebert K, Ormiston J, Serruys PW. Brugaletta S, et al. Among authors: miquel hebert k. Atherosclerosis. 2012 Mar;221(1):106-12. doi: 10.1016/j.atherosclerosis.2011.12.008. Epub 2011 Dec 13. Atherosclerosis. 2012. PMID: 22209268 Clinical Trial.
23 results